Compare Ascendis Pharma A/S (ASND) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Mesoblast Limited — how do they compare? Ascendis Pharma A/S trades at $254.01 (market cap $16.67B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Ascendis Pharma A/S is far larger — about 7.5× Mesoblast Limited's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ASND | MESO | |
|---|---|---|
Market Cap | $16.67B | $2.21B |
Sector | Health | Technology |
52-Week High | $277.18 | $20.96 |
52-Week Low | $189.74 | $12.88 |
Enterprise Value | $17.04B | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
